NCT03323528View on ClinicalTrials.gov

Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis

PHASE4CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

July 2, 2017

Study Completion Date

November 15, 2017

Conditions
Pharyngitis
Interventions
DRUG

Benzalkonium Chloride-Benzocaine Topical

Dorithricin = tyrothricin, benzalkonium chloride, benzocaine

DRUG

Placebo Oral Tablet

"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."

Trial Locations (1)

90552

doc-HNO for the DoriPha investigators, Röthenbach an der Pegnitz

All Listed Sponsors
collaborator

University Hospital Muenster

OTHER

lead

Medice Arzneimittel Pütter GmbH & Co KG

INDUSTRY

NCT03323528 - Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis | Biotech Hunter | Biotech Hunter